Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

15.53
+0.07000.45%
Post-market: 15.52-0.0100-0.06%19:30 EDT
Volume:567.53K
Turnover:8.84M
Market Cap:999.43M
PE:-4.48
High:15.95
Open:15.41
Low:15.24
Close:15.46
52wk High:23.19
52wk Low:6.50
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.46
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:3.11
PE(LYR):-4.17

Loading ...

Cullinan Therapeutics - Expects Phase 1 Cln-049 Study Update in December

THOMSON REUTERS
·
Oct 08

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of Cln-049 in Relapsed/Refractory Acute Myeloid Leukemia

THOMSON REUTERS
·
Oct 08

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

GlobeNewswire
·
Oct 08

Cullinan Management (CGEM) Gets a Buy from Wedbush

TIPRANKS
·
Oct 07

Cullinan Therapeutics (CGEM) Starts Zipalertinib NDA Submission, Is The Stock Still 52% Undervalued?

Simply Wall St.
·
Oct 07

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)

TIPRANKS
·
Oct 02

Cullinan Therapeutics Price Target Maintained with a $35.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 02

Cullinan Management Advances NDA for Zipalertinib Combination

TIPRANKS
·
Oct 02

Cullinan Initiates FDA NDA Submission for Zipalertinib Plus Chemotherapy Under RTOR Program

Reuters
·
Oct 02

Cullinan Starts FDA Submission for Zipalertinib-Chemotherapy Combo in Non-Small Cell Lung Cancer

MT Newswires Live
·
Oct 02

Cullinan Therapeutics initiates NDA for Zipalertinib

TIPRANKS
·
Oct 02

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line Egfr Exon 20 Insertion Mutation Nsclc for Review Under FDA Real-Time Oncology Review Program

THOMSON REUTERS
·
Oct 02

Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN) and Cullinan Management (CGEM)

TIPRANKS
·
Sep 25

Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright

TIPRANKS
·
Sep 25

Cullinan Therapeutics Price Target Maintained with a $40.00/Share by BTIG

Dow Jones
·
Sep 25

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Reuters
·
Sep 25

Matt Phipps Reiterates Buy on Cullinan Oncology, Citing Pullback-Driven Upside and Upcoming Q4 Clinical Data Catalysts

TIPRANKS
·
Sep 25

Cullinan Therapeutics share weakness provides buying opportunity, says TD Cowen

TIPRANKS
·
Sep 25

Cullinan falls after pushing rheumatoid arthritis data to December

TIPRANKS
·
Sep 24

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

GlobeNewswire
·
Sep 24